Ohmyhome Ltd. was notified by Nasdaq on July 13, 2026, that its share price fell below the required $1 minimum bid price, risking delisting from the Nasdaq Capital Market. The company has 180 days, until January 11, 2027, to restore its share price above $1 for at least 10 consecutive days to regain compliance. If it fails, it may get an additional 180-day extension if it meets other listing criteria and plans to fix the issue, possibly through a reverse stock split. Ohmyhome is evaluating options to meet Nasdaq's requirements and maintain its listing status.
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
TOMI Environmental Solutions reported a 118% year-over-year revenue increase to $2.25 million, surpassing analyst estimates of $1.84 million. The company also beat EPS expectations with a loss of $0.05 per share, better than the anticipated loss of $...
Seaport Global raised the price target for Madison Square Garden Sports Corp. to $473, reflecting a 17.13% potential upside. The company reported strong fiscal Q4 results with earnings per share of $1.19, beating estimates of $0.72, and revenue risin...
Airbus is outperforming Boeing in commercial aircraft orders, securing 821 net orders in H1 2026 compared to Boeing's 408. Morgan Stanley maintains an "Overweight" rating on Airbus, raising its price target to €255, reflecting confidence in the compa...
PAVmed reported a Q2 2026 GAAP loss per share of $0.87 and a non-GAAP loss of $0.27, beating analyst expectations of a $0.47 loss. Revenue was $33,000, below the $49,000 consensus. Lucid Diagnostics, an investment of PAVmed, generated $1.5 million in...
